Physician profile
Mary E Jones
NPI 1740232099
$2,522.17
in general payments reported to CMS, 2019-2025
23 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.59 · 2020: $13.77 · 2021: $368 · 2022: $801 · 2023: $567 · 2024: $371 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $898.21 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $289.16 | 2021-2025 | |
| Abbott Laboratories | $265.30 | 2021-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Amgen INC. | $236.46 | 2021-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $132.14 | 2021-2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $100.46 | 2023-2025 | Intellis Adaptivestim, Vectris Surescan, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $95.70 | 2021-2023 | |
| Glaxosmithkline, LLC. | $72.44 | 2023-2025 | Arexvy, Shingrix |
| Ibsa Pharma INC. | $68.08 | 2022 | |
| Astellas Pharma US INC | $48.00 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.78 | 2021-2024 | Jardiance |
| Bausch Health US, LLC | $44.27 | 2022-2023 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $37.92 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.74 | 2022 | |
| Pfizer INC. | $26.97 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.49 | 2022 | |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $16.97 | 2025 | Evkeeza |
| Sumitomo Pharma America, INC. | $16.65 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $15.72 | 2025 | Nexletol |
| Amarin Pharma, INC. | $15.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.